Finerenone (BAY94-8862) + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-diabetic Chronic Kidney Disease
Conditions
Non-diabetic Chronic Kidney Disease
Trial Timeline
Sep 21, 2021 → Feb 2, 2026
NCT ID
NCT05047263About Finerenone (BAY94-8862) + Placebo
Finerenone (BAY94-8862) + Placebo is a phase 3 stage product being developed by Bayer for Non-diabetic Chronic Kidney Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05047263. Target conditions include Non-diabetic Chronic Kidney Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05047263 | Phase 3 | Completed |
| NCT04795726 | Pre-clinical | Completed |
| NCT02540993 | Phase 3 | Completed |
| NCT02545049 | Phase 3 | Completed |
| NCT01874431 | Phase 2 | Completed |
Competing Products
3 competing products in Non-diabetic Chronic Kidney Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Qutenza + Pregabalin | Astellas Pharma | Approved | 85 |
| Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mg | AstraZeneca | Approved | 85 |
| Aliskiren + Placebo to Aliskiren + Hydrochlorothiazide (HCTZ) + Placebo to Hydrochlorothiazide (HCTZ) + Ramipril | Novartis | Phase 2 | 52 |